Head-To-Head Comparison: Qiagen (NYSE:QGEN) & Pluristem Therapeutics (NYSE:PSTI)

Share on StockTwits

Qiagen (NYSE:QGEN) and Pluristem Therapeutics (NASDAQ:PSTI) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, dividends, profitability, institutional ownership, analyst recommendations, risk and valuation.

Insider & Institutional Ownership

65.0% of Qiagen shares are held by institutional investors. Comparatively, 6.0% of Pluristem Therapeutics shares are held by institutional investors. 9.0% of Qiagen shares are held by insiders. Comparatively, 6.7% of Pluristem Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Qiagen and Pluristem Therapeutics, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Qiagen 0 3 8 0 2.73
Pluristem Therapeutics 0 0 3 0 3.00

Qiagen presently has a consensus price target of $42.40, suggesting a potential upside of 22.69%. Pluristem Therapeutics has a consensus price target of $35.00, suggesting a potential upside of 823.48%. Given Pluristem Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Pluristem Therapeutics is more favorable than Qiagen.

Earnings and Valuation

This table compares Qiagen and Pluristem Therapeutics’ top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Qiagen $1.50 billion 5.19 $190.38 million $1.34 25.79
Pluristem Therapeutics $50,000.00 1,160.65 -$26.12 million ($2.50) -1.52

Qiagen has higher revenue and earnings than Pluristem Therapeutics. Pluristem Therapeutics is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Qiagen has a beta of 0.83, indicating that its share price is 17% less volatile than the S&P 500. Comparatively, Pluristem Therapeutics has a beta of 0.89, indicating that its share price is 11% less volatile than the S&P 500.

Profitability

This table compares Qiagen and Pluristem Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Qiagen 12.94% 12.10% 5.76%
Pluristem Therapeutics N/A -197.88% -129.44%

Summary

Qiagen beats Pluristem Therapeutics on 10 of the 14 factors compared between the two stocks.

About Qiagen

QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers sample technologies for plasmid deoxyribonucleic acid (DNA) purification, ribonucleic acid purification and stabilization, genomic and viral nucleic acid purification, DNA cleanup after polymerase chain reaction (PCR) and sequencing, target enrichment, and library preparation for sequencing applications; and assay technology solutions. It also provides Ingenuity Variant Analysis, an application for analysis and interpretation of human sequencing data generated with next-generation sequencing (NGS) technologies; QIAGEN Clinical Insight, an evidence-based variant classification; CLC Genomics Workbench for the analysis and visualization of data from various NGS platforms; and GeneGlobe, a Web-based portal that enables researchers to search and order bioinformatics solutions and linking biological interpretation from pre-designed and custom PCR assay kits, NGS assay panels, and other products. In addition, the company offers instrumentation systems for laboratories. Its automation platforms include QIAsymphony, a modular system; QIAsymphony SP for sample preparation; QIAsymphony AS for assay setup; Rotor-Gene Q, a rotary real-time PCR cycler system; QIAstat-Dx for molecular analysis of common syndromes; GeneReader NGS System, a sample to insight NGS solution for laboratories to deliver actionable results; NeuMoDx 288 and NeuMoDx 96 for automation of higher-throughput PCR testing in clinical laboratories; and QIAcube and QIAcube connect workstations, which provides versatile solutions for automated sample processing; It serves molecular diagnostics, applied testing, pharma, and academia customers. QIAGEN N.V. has collaboration agreements with Ares Genetics and Laboratory Corporation of America Holdings. The company was founded in 1986 and is headquartered in Venlo, the Netherlands.

About Pluristem Therapeutics

Pluristem Therapeutics Inc., together with its subsidiary, Pluristem Ltd., operates as a bio-therapeutics company in Israel. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders. The company develops PLacental eXpanded (PLX) cell therapy products, including PLX-PAD cells, which is Phase III clinical trial for the treatment of critical limb ischemia (CLI) in patients ineligible for revascularization, recovery after surgery for hip fracture, and acute radiation syndrome (ARS), as well as peripheral and cardiovascular, and orthopedic diseases. It also develops PLX-R18 cells that is in Phase I clinical trial for incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as conducts various animal studies for the evaluation of PLX-R18 for the treatment of ARS. The company has collaborative research agreement with the Berlin-Brandenburg Center for Regenerative Therapies; a license and commercialization agreement for conducting clinical trials and commercialization of its PLX-PAD product in South Korea related to the treatment CLI and intermediate claudication; and nTRACK, a collaborative project with Leitat to examine gold nano particles labeling of stem cells. It also has a collaboration agreement with the NASA's Ames Research Center to evaluate the potential of PLX cell therapies in preventing and treating medical conditions caused during space missions. Pluristem Therapeutics Inc. was founded in 2001 and is based in Haifa, Israel.

Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply